We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETRM
276
DELISTED
EnteroMedics Inc.
ETRM
$67K ﹤0.01%
+33,387
New +$175K
ATHX
277
DELISTED
Athersys, Inc. Common Stock
ATHX
$66K ﹤0.01%
1,731
-1,835
-51% -$80.7K
RCKT icon
278
CALL
Rocket Pharmaceuticals
RCKT
$343M
$65K ﹤0.01%
27
– –
ANTH
279
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$64K ﹤0.01%
123
-142
-54% -$2.46K
PALI icon
280
Palisade Bio
PALI
$351M
– –
-2
Closed -$655K
ANTH
281
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$59K ﹤0.01%
11,382
-393
-3% -$6.8K
XYLO
282
DELISTED
Xylo Technologies
XYLO
$50K ﹤0.01%
55
-597
-92% -$936K
SLS icon
283
SELLAS Life Sciences
SLS
$1.98B
$45K ﹤0.01%
+16
New +$93K
GPL
284
PUT
DELISTED
Great Panther Mining Limited
GPL
$45K ﹤0.01%
+27
New +$374
DMK
285
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$42K ﹤0.01%
2
– –
VKTXW
286
DELISTED
Viking Therapeutics, Inc.
VKTXW
$39K ﹤0.01%
86,349
-30,659
-26% -$13K
TENX icon
287
PUT
Tenax Therapeutics
TENX
$419M
– –
0
– –
RIGL icon
288
Rigel Pharmaceuticals
RIGL
$712M
$29K ﹤0.01%
1,235
-7,455
-86% -$214K
GALT icon
289
PUT
Galectin Therapeutics
GALT
$223M
$23K ﹤0.01%
235
-590
-72% -$524
NVAX icon
290
CALL
Novavax
NVAX
$1.21B
$20K ﹤0.01%
8
-102
-93% -$2.98K
BNTCW
291
DELISTED
Benitec Biopharma Limited
BNTCW
$10K ﹤0.01%
+98,146
New +$9.9K
EYEGW
292
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$6K ﹤0.01%
20,604
-26,364
-56% -$10.4K
ABT icon
293
CALL
Abbott
ABT
$187B
– –
-555
Closed -$2.35M
ABT icon
294
Abbott
ABT
$187B
– –
-112,888
Closed -$4.77M
ABT icon
295
PUT
Abbott
ABT
$187B
– –
-5,000
Closed -$21.1M
ACHC icon
296
CALL
Acadia Healthcare
ACHC
$3.01B
– –
-7,784
Closed -$24.8M
ACHC icon
297
PUT
Acadia Healthcare
ACHC
$3.01B
– –
-548
Closed -$1.74M
ASMB icon
298
Assembly Biosciences
ASMB
$507M
– –
-6,267
Closed -$542K
AVXL icon
299
PUT
Anavex Life Sciences
AVXL
$238M
– –
-858
Closed -$311K
AZN icon
300
CALL
AstraZeneca
AZN
$267B
– –
-1,760
Closed -$11.6M
10 11
12
13 14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.